EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Infants with Retinopathy of Prematurity Treated with Intravitreal Bevacizumab

Sarkhan Elbayiyev, Özdemir Özdemir, Burak Ceran, Mustafa Şenol Akın, Fuat Emre Canpolat, Suna Oguz

Turkish Journal of Pediatric Disease · 2022

DOI: 10.12956/tchd.1003824 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Pediatric Disease, 2022. Verfasst von Sarkhan Elbayiyev und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the systemic and local effects and side effects of intravitreal bevacizumab injection in preterm infants with aggressive posterior retinopathy of prematurity. Material and Methods: A total of 16 patients were included in this single-center observational cohort study between June 2020 and March 2021. The clinical, laboratory, and radiological findings before and after intravitreal injection of 0.3 mg bevacizumab were recorded for a total of 32 eyes.

Results

The patients’ mean gestational age at birth was 25±0.38 weeks and their mean birth weight was 695±119.2 g. None of the patients developed complications such as local vitreous hemorrhage or endophthalmitis secondary to intravitreal injection administered at a postmenstrual age of 34 weeks, and none required repeated injections. There was no increase in the rate of intraventricular hemorrhage after injection. There was no statistically significant difference in the patients’ laboratory parameters, blood pressure values, or systemic findings before and after treatment.

Conclusion

Although no systemic or local side effects were observed in patients treated with intravitreal bevacizumab injection in this study, patients should be monitored closely for systemic hypertension, intraventricular hemorrhage, and hypotension. More detailed studies are needed to evaluate later neurodevelopmental outcomes compared to other treatment options.

Zitieren

APA

Elbayiyev, S., Özdemir, Ö., Ceran, B., Akın, M. Ş., Canpolat, F. E., & Oguz, S. (2022). Evaluation of Infants with Retinopathy of Prematurity Treated with Intravitreal Bevacizumab. Turkish Journal of Pediatric Disease. https://doi.org/10.12956/tchd.1003824

Vancouver

Elbayiyev S, Özdemir Ö, Ceran B, Akın MŞ, Canpolat FE, Oguz S. Evaluation of Infants with Retinopathy of Prematurity Treated with Intravitreal Bevacizumab. Turkish Journal of Pediatric Disease. 2022. doi:10.12956/tchd.1003824

BibTeX
@article{Elbayiyev2022,
  author = {Elbayiyev, Sarkhan and Özdemir, Özdemir and Ceran, Burak and Akın, Mustafa Şenol and Canpolat, Fuat Emre and Oguz, Suna},
  title = {Evaluation of Infants with Retinopathy of Prematurity Treated with Intravitreal Bevacizumab},
  journal = {Turkish Journal of Pediatric Disease},
  year = {2022},
  doi = {10.12956/tchd.1003824}
}
Kostenlos starten →